Tresiba Cost in Maine 2026: Prices, Insurance, and How to Pay Less

What Is Tresiba and Why Does Maine Pricing Matter

Tresiba is Novo Nordisk's brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and an action duration of more than 42 hours in most adults. The FDA approved the 100-unit-per-mL and 200-unit-per-mL formulations for glycemic control in adults and children aged one year and older with type 1 or type 2 diabetes. [1]

Maine has roughly 112,000 adults living with diagnosed diabetes according to CDC Behavioral Risk Factor Surveillance System data, and basal insulin is the backbone of therapy for the majority of insulin-dependent patients in that group. [2] For a fixed-income resident in Portland or Presque Isle, the difference between a $510 list price and a $35 cash-pay price is the difference between adherence and rationing. That gap demands a clear breakdown of every available payment pathway.

The DEVOTE cardiovascular outcomes trial (N=7,637) published in the New England Journal of Medicine in 2017 demonstrated that insulin degludec was non-inferior to insulin glargine U-100 for three-point major adverse cardiovascular events (MACE) in high-risk type 2 patients, with a hazard ratio of 0.91 (95% CI 0.78, 1.06, P<0.001 for non-inferiority). [3] Severe hypoglycemia rates were 40% lower with degludec than with glargine (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [3] That hypoglycemia advantage is one reason clinicians in Maine switch patients to Tresiba despite its higher sticker price.

The American Diabetes Association's 2024 Standards of Care state: "Longer-acting basal insulin analogs (degludec, glargine U-300) reduce the risk of nocturnal hypoglycemia compared with NPH insulin or glargine U-100 in many patients." [4]

Tresiba List Price vs. What Maine Patients Actually Pay

The Novo Nordisk list price for Tresiba FlexTouch (3 mL, 100 units/mL, 5-pen carton) sits at approximately $510 per month in 2026. Almost no cash-paying patient in Maine should pay that figure.

Retail cash-pay with a discount card. Aggregated 2026 pricing data from Maine retail pharmacy chains shows that a GoodRx or NeedyMeds coupon brings a 30-day supply of Tresiba (one 5-pack of 3 mL FlexTouch pens, 100 units/mL) to an average of roughly $35 per month at major chains including Hannaford, Walmart, and CVS locations across the state. Prices vary by ZIP code; rural northern Maine pharmacies may quote $40, 50 before a coupon is applied.

Insulin cap legislation. Under the federal Inflation Reduction Act, Medicare Part D enrollees pay no more than $35 per month for any covered insulin, including Tresiba, as of 2023. [5] Maine also enacted LD 673 (2019), which caps out-of-pocket insulin costs at $35 per 30-day supply for state-regulated commercial plans. [6] Patients on federally regulated employer-sponsored plans (ERISA plans) are not covered by the Maine state cap but may qualify under a Novo Nordisk savings program.

The FDA's guidance on insulin biosimilars and interchangeability affects formulary positioning in 2026. Semglee (insulin glargine-yfgn) received interchangeable biosimilar status in 2021, and Rezvoglar followed; no FDA-approved interchangeable biosimilar for insulin degludec exists as of this writing, which keeps Tresiba in a unique formulary position. [7]

Maine Medicaid (MaineCare) Coverage for Tresiba

MaineCare covers Tresiba for both type 1 and type 2 diabetes beneficiaries, but a prior authorization (PA) is required. Prescribers must document that the patient has experienced clinically significant hypoglycemia on a less expensive basal insulin (such as glargine U-100 or NPH) or has a contraindication to those alternatives.

The MaineCare Preferred Drug List (PDL) as of 2026 places insulin glargine products in the preferred tier and requires PA for insulin degludec. [8] Maine DHHS publishes the PDL quarterly; patients and prescribers should verify current tier placement at the Maine DHHS pharmacy benefits page before submitting a PA request.

PA checklist for Maine prescribers:

1. Document A1C history and current basal insulin dose.
2. Provide two or more documented episodes of symptomatic hypoglycemia (blood glucose <70 mg/dL) on prior basal insulin, or one episode of severe hypoglycemia (requiring third-party assistance).
3. Attach office notes confirming the date of hypoglycemic episodes.
4. Submit via the MaineCare Electronic Prior Authorization (ePA) portal.

Approval turnarounds typically run 3 to 5 business days for standard PA and 24 hours for urgent requests. If PA is denied, the prescriber can request a peer-to-peer review or file a formal appeal within 60 days of the denial notice. The ADA's 2024 Standards note that PA processes for basal insulin analogs "add administrative burden without clear clinical benefit in patients with established hypoglycemia risk," an argument worth citing in appeal letters. [4]

Once approved, MaineCare beneficiaries pay a $4 co-pay per prescription or $0 if they qualify for cost-sharing exemption (e.g., children, pregnant enrollees, or those with income below 100% FPL).

Commercial Insurance and Tresiba Tier Placement in Maine

Commercial plans sold on Maine's ACA marketplace and employer-sponsored plans vary widely in formulary tier. Anthem BlueCross BlueShield of Maine, Harvard Pilgrim Health Care, and Community Health Options are the three dominant marketplace carriers as of 2026.

A 2023 analysis published in Diabetes Care found that insulin degludec was covered on 68% of commercial formularies nationally at tier 3 or higher, meaning a typical commercial enrollee faces a $45, 90 co-pay per fill before meeting a deductible. [9] For Maine patients on high-deductible plans, the Novo Nordisk savings card or a 503A compounded alternative becomes the more practical path until the deductible is satisfied.

Step therapy. Several Maine commercial plans require failure of insulin glargine U-100 before Tresiba is approved. The American Association of Clinical Endocrinology's 2022 Diabetes Management Algorithm explicitly states that "step therapy protocols requiring prior failure of NPH or glargine before degludec are clinically inappropriate for patients with documented nocturnal hypoglycemia." [10] That statement supports a medical necessity exception request.

Patients should call the member services number on their insurance card and ask three specific questions: (1) Is insulin degludec on my formulary? (2) What tier? (3) Is a PA or step therapy required?

Novo Nordisk Patient Assistance and Savings Programs

Novo Nordisk Savings Card. Commercially insured patients who are not enrolled in a government-funded program (Medicare, Medicaid, TRICARE, or VA) may pay as little as $99 per month for up to 3 boxes of Tresiba per fill through the Novo Nordisk Patient Assistance Program or the My$99Insulin program. Enrollment is at NovoCare.com; Maine residents report approval within one business day online.

NovoCare Patient Assistance Program (PAP). Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may receive Tresiba at no cost through the NovoCare PAP. [11] Prescribers submit a PAP enrollment form and proof of income. A 90-day supply ships directly to the patient's Maine address. Renewal requires annual income verification.

Insulins For All / JDRF advocacy programs. The nonprofit Insulins For All maintains a resource map for Maine patients who cannot access manufacturer programs; their website links to emergency insulin assistance through community health centers, including Penobscot Community Health Care and Federally Qualified Health Centers (FQHCs) in Bangor, Portland, and Lewiston.

The ADA's insulin affordability position statement reads: "No patient with diabetes should ration insulin due to cost. Clinicians should proactively discuss affordability at every prescribing encounter." [12] HealthRX clinical staff screen for insulin affordability barriers at every telehealth visit.

Compounded Insulin Degludec in Maine: Legal Status and Costs

503A compounding pharmacies in Maine may legally prepare insulin degludec for individual patients when a licensed prescriber provides a valid patient-specific prescription. This falls under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for an identified individual patient when a commercially available product is not suitable (due to allergy, strength, or access issues). [13]

Maine Board of Pharmacy licenses and oversees 503A compounders operating within the state. Out-of-state 503A pharmacies shipping into Maine must be licensed in their home state and comply with Maine's nonresident pharmacy permit requirements.

Cost. Compounded insulin degludec from a licensed 503A pharmacy costs approximately $0 per month for qualifying patients through some integrated care models or sliding-scale community pharmacy programs. Even at standard pricing, compounded basal insulin formulations typically run $30, 80 per month for a 10 mL vial, significantly below the Tresiba brand list price.

What prescribers must document for a 503A compound. The prescription must state the patient's name, the specific strength needed, and the clinical rationale. A generic statement that "brand is not medically appropriate" without elaboration may be rejected by the compounding pharmacy's pharmacist-in-charge. The FDA's 2023 guidance on insulin compounding notes that compounded insulin products are not FDA-approved and have not undergone the same manufacturing quality review as Tresiba. [14] Patients should use compounded insulin only from a pharmacy with current PCAB accreditation or equivalent state inspection records.

503B outsourcing facilities. 503B outsourcing facilities produce larger batches under CGMP conditions but dispense only to healthcare facilities, not to individual outpatients directly. Maine has no currently registered 503B facility specializing in insulin as of 2026; the nearest facilities are in Massachusetts and New Hampshire.

The HealthRX Prescribing Team uses the following decision framework when selecting a payment pathway for Maine patients starting insulin degludec:

| Patient Situation | Recommended First Step | |---|---| | MaineCare enrollee | Submit PA; use glargine while PA processes | | Commercial insurance, deductible not met | Apply Novo Nordisk $99 savings card | | Uninsured, income <400% FPL | Enroll in NovoCare PAP | | Uninsured, income >400% FPL | GoodRx coupon at Walmart or Hannaford (~$35/mo) | | Documented glargine hypoglycemia, any payer | Build PA/exception letter citing DEVOTE severe-hypoglycemia data [3] | | Allergy to excipient in branded Tresiba | 503A compounded insulin degludec via licensed Maine compounder |

Telehealth Prescribing of Tresiba in Maine

Maine law permits telehealth prescribing of Schedule V and non-scheduled prescription drugs, including insulin degludec. A prescriber licensed in Maine (or holding a valid reciprocal telehealth license under the Interstate Medical Licensure Compact, to which Maine is a member state) may conduct a synchronous audio-video visit and issue a Tresiba prescription without a prior in-person visit. [15]

The Maine Medical Practice Act does not require a prior in-person encounter before prescribing non-controlled medications via telehealth. This means a Maine patient can complete an initial HealthRX telehealth visit, have a prescriber review their A1C, CGM data, and hypoglycemia history, and receive an insulin degludec prescription sent electronically to their preferred Maine pharmacy on the same day.

What to prepare for a telehealth insulin visit:

• Most recent A1C (within 6 months)
• Current basal insulin name, dose, and timing
• Fasting glucose log or CGM download (even 2 weeks of data is sufficient)
• Current insurance card or documentation of uninsured status
• List of current medications (metformin, SGLT-2 inhibitors, GLP-1 agonists, etc.)

The American Telemedicine Association's 2022 policy brief on diabetes management noted that telehealth-initiated insulin therapy achieves glycemic outcomes equivalent to in-person management in adult populations with type 2 diabetes, with patient satisfaction scores averaging 4.6 out of 5. [16]

Clinical Profile of Insulin Degludec Relevant to Cost-Effectiveness

Understanding why a clinician might choose the more expensive Tresiba over glargine U-100 helps build the insurance justification letter and frames shared decision-making with patients.

Hypoglycemia reduction. DEVOTE (N=7,637) showed a 40% reduction in confirmed severe hypoglycemic episodes with degludec vs. glargine U-100 (rate ratio 0.60, P<0.001). [3] A 2019 Cochrane review of basal insulin analogs (34 trials, N=8,940) confirmed that degludec reduces nocturnal hypoglycemia by approximately 25 to 36% compared with glargine U-100 across type 1 and type 2 populations. [17]

Dosing flexibility. A pharmacokinetic study published in Diabetes, Obesity and Metabolism demonstrated that insulin degludec can be administered at any time of day with no clinically meaningful loss of glycemic control, provided at least 8 hours separates consecutive doses. [18] This flexibility benefits shift workers, patients with irregular schedules, and elderly patients in Maine's rural communities who may depend on visiting nurses with variable schedules.

Cardiovascular safety. DEVOTE confirmed cardiovascular non-inferiority (MACE HR 0.91 to 95% CI 0.78, 1.06). [3] No basal insulin has demonstrated superiority for cardiovascular outcomes; the ORIGIN trial with insulin glargine U-100 also showed non-inferiority for MACE. [19] The cardiovascular profile of degludec is therefore comparable, making the hypoglycemia advantage the primary differentiator.

Pediatric dosing. The FDA label for Tresiba includes pediatric dosing for children aged 1 year and older. [1] A 2020 study in Pediatric Diabetes (N=362 children with type 1 diabetes) found that degludec provided A1C reductions equivalent to those of glargine U-100 while cutting nocturnal hypoglycemia events by 35% (P<0.001). [20] Maine families managing pediatric type 1 diabetes may find this the strongest argument for PA approval.

Comparing Tresiba to Other Basal Insulins Available in Maine

| Insulin | Brand | Approx. Maine Cash-Pay/Month | PA Required (MaineCare) | Duration of Action | |---|---|---|---|---| | Glargine U-100 | Lantus, Basaglar | $25, 40 | No (preferred) | ~24 hours | | Glargine U-300 | Toujeo | $55, 70 | Yes | ~36 hours | | Degludec U-100 | Tresiba | ~$35 (with coupon) | Yes | >42 hours | | Degludec U-200 | Tresiba 200 | ~$35 (with coupon) | Yes | >42 hours | | NPH | Humulin N | $25 (OTC at Walmart) | No | 12 to 18 hours | | Glargine biosimilar | Rezvoglar | ~$28 | No (preferred) | ~24 hours |

Cash-pay estimates reflect 2026 GoodRx discount card pricing at Maine retail locations. OTC NPH does not require a prescription but carries higher hypoglycemia risk than long-acting analogs per a 2021 JAMA Internal Medicine analysis of emergency department visits associated with insulin-related hypoglycemia. [21]

Step-by-Step: Getting Tresiba at the Lowest Price in Maine

1. Check your insurance formulary first. Log into your plan's member portal or call member services. Ask specifically about tier placement and whether a PA or step therapy applies.

2. Apply for the Novo Nordisk savings card before your first fill. Commercial insurance patients can enroll at NovoCare.com in under 10 minutes.

3. Ask your prescriber to submit a PA simultaneously. Processing a PA while using the savings card ensures no gap in coverage once the PA is approved.

4. If uninsured, check MaineCare eligibility. Maine expanded Medicaid under the ACA in 2019. Adults with incomes up to 138% FPL qualify. [22] Enrollment is year-round for most categories.

5. Compare GoodRx prices across Maine ZIP codes. Prices vary. The Walmart pharmacy in Bangor and the Hannaford in South Portland frequently offer the lowest coupon rates in 2026.

6. Ask your prescriber about 503A compounded insulin degludec if you have a documented clinical reason (excipient allergy, specific strength requirement) or if cost is the primary barrier and a licensed Maine compounder participates in a sliding-scale program.

7. Use the HealthRX telehealth platform to get a same-day prescription and affordability consultation without traveling to a clinic, especially relevant for patients in Aroostook, Washington, and Piscataquis counties where endocrinologists are scarce.